I-Caerin 1.1

I-Caerin 1.1 is an investigational modified host-defense peptide developed by Zhongao Biomedical Technology, derived from the skin secretions of Australian tree frogs (genus *Litoria*). It is a variant of the parent peptide Caerin 1.1, specifically engineered for use in internal radiation therapy as a radioimmunoconjugate (often referred to as I-c(RGD)). The drug functions as both an immunomodulator and a pro-pyroptotic agent. Its mechanism of action involves the inhibition of the IL-10R1 signaling pathway to overcome tumor-induced immunosuppression and the activation of the IFN-α/STAT1 pathway to promote M1 macrophage polarization within the tumor microenvironment. Additionally, I-Caerin 1.1 induces pyroptosis in cancer cells by activating the caspase-3/GSDME (Gasdermin E) pathway. It is currently in preclinical development for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer, leveraging its dual action of targeted radiotherapy and immune enhancement.

Other names

modified Caerin 1.1I-Caerin 1.1 radioimmunoconjugateI-Caerin1.1 radioimmunoconjugateI-Caerin-1.1 radioimmunoconjugate